PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21320474-7	2011	Moreover, zonisamide increased the number of S100beta-positive and glial fibrillary acidic protein (GFAP)-positive astrocytes and dopamine turnover.	Zonisamide	10-20	glial fibrillary acidic protein	Mus musculus	67-98	
21320474-7	2011	Moreover, zonisamide increased the number of S100beta-positive and glial fibrillary acidic protein (GFAP)-positive astrocytes and dopamine turnover.	Zonisamide	10-20	glial fibrillary acidic protein	Mus musculus	100-104	
19199078-4	2009	We observed that zonisamide attenuated MPTP-induced dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) depletion in the striatum and reduced the loss of tyrosine hidroxylase (TH) positive neurons and the increase of glial fibrillary acidic protein (GFAP) positive astrocytes in the striatum and substantia nigra after 5 days.	Zonisamide	17-27	glial fibrillary acidic protein	Mus musculus	243-274	
19199078-4	2009	We observed that zonisamide attenuated MPTP-induced dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) depletion in the striatum and reduced the loss of tyrosine hidroxylase (TH) positive neurons and the increase of glial fibrillary acidic protein (GFAP) positive astrocytes in the striatum and substantia nigra after 5 days.	Zonisamide	17-27	glial fibrillary acidic protein	Mus musculus	276-280	
19199078-5	2009	Our Western blot analysis study also showed that zonisamide can prevent the decrease of TH protein levels and increase of GFAP protein levels in the striatum 5 days after MPTP treatment.	Zonisamide	49-59	glial fibrillary acidic protein	Mus musculus	122-126